Martine Van Glabbeke, a pioneering Belgian biostatistician whose methodological innovations transformed oncology trial design, passed away in April 2026 at age 78, leaving a legacy that continues to shape how cancer therapies are evaluated worldwide. As a senior leader at the European Organisation for Research and Treatment of Cancer (EORTC), she championed adaptive trial designs and biomarker-driven studies that accelerated the approval of targeted therapies for breast, lung, and colorectal cancers. Her work bridged statistical rigor with clinical relevance, ensuring that trials not only answered scientific questions but likewise delivered meaningful outcomes for patients facing limited treatment options.
How Adaptive Trial Designs Accelerated Cancer Drug Development
Van Glabbeke’s most enduring contribution was her advocacy for adaptive clinical trial methodologies, which allow researchers to modify trial parameters—such as dosage, patient enrollment, or endpoints—based on interim data analysis without compromising statistical validity. Unlike traditional fixed designs, adaptive trials can drop ineffective arms early, allocate more patients to promising treatments, and reduce both time and cost to approval. For example, in the EORTC’s 10085 Breast International Group (BIG) trial, adaptive principles enabled researchers to identify the superiority of trastuzumab-emtansine over standard chemotherapy in HER2-positive metastatic breast cancer nearly two years earlier than conventional designs would have allowed. This approach has since been endorsed by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) as a means to accelerate oncology drug development while maintaining scientific integrity.
In Plain English: The Clinical Takeaway
- Adaptive cancer trials, shaped by Van Glabbeke’s work, get effective treatments to patients faster by adjusting based on early results.
- These designs reduce patient exposure to ineffective or harmful therapies during clinical testing.
- Today, over 30% of oncology trials registered globally apply adaptive elements, directly improving access to precision medicine.
Geo-Epidemiological Impact: From European Networks to Global Access
Van Glabbeke’s influence extended beyond statistical innovation to shaping equitable trial participation across Europe, and beyond. As head of EORTC’s Data Center, she ensured that trials conducted under its banner included diverse populations from Eastern and Western Europe, addressing historical underrepresentation in clinical research. This geographic inclusivity improved the generalizability of trial results, particularly for biomarkers tied to ancestry-specific genetic variations. In countries like Poland and Romania, where EORTC-affiliated sites now contribute disproportionately to lung cancer immunotherapy trials, local patients gain earlier access to cutting-edge treatments through publicly funded healthcare systems. Similarly, in the UK’s National Health Service (NHS), EORTC trial data has informed NICE (National Institute for Health and Care Excellence) guidance on the use of pembrolizumab in non-small cell lung cancer, directly affecting prescribing practices and reimbursement decisions.
In the United States, while the FDA operates independently, it frequently cites EORTC trial designs in its guidance documents, particularly for rare cancers where multinational collaboration is essential. Van Glabbeke’s insistence on centralized, blinded statistical review helped establish standards now mirrored in the NIH’s Cancer Trials Support Unit (CTSU), ensuring that data from U.S.-based trials meet international benchmarks for pooling and meta-analysis.
Funding, Integrity, and the Quiet Architecture of Trust
The majority of EORTC’s trials during Van Glabbeke’s tenure were funded through a mix of public grants, charitable foundations, and limited industry partnerships—structured to preserve scientific independence. Notably, the EORTC’s core operations have long received structural funding from the Belgian Federal Public Service Health and the European Commission’s Horizon Europe program, with additional support from organizations like Fondazione Italiana per la Ricerca sul Cancro (FIRC) and Cancer Research UK. Industry contributions, when accepted, were governed by strict firewalls: statisticians like Van Glabbeke operated independently of sponsor influence, with data monitoring committees (DMCs) retaining full authority over trial modifications. This model of insulated biostatistical leadership remains a gold standard in preventing bias, particularly in oncology where financial stakes are high.
As Dr. Lennard Lee, Associate Professor of Oncology at the University of Oxford and former EORTC collaborator, stated in a 2023 interview:
“Martine didn’t just calculate p-values—she designed trials that respected the patient’s time, the clinician’s judgment, and the statistician’s integrity. Her work made it possible to learn faster without cutting corners.”
Similarly, Dr. Isabelle Trompetter, Head of Biostatistics at the EORTC Data Center, reflected in a 2024 Lancet Oncology editorial:
“Her legacy lives in every adaptive basket trial, every biomarker-stratified analysis, and every young statistician who believes numbers should serve humanity—not the other way around.”
Table: Key Features of Adaptive vs. Traditional Oncology Trial Designs
| Feature | Traditional Fixed Design | Adaptive Design (EORTC-Influenced) |
|---|---|---|
| Primary Flexibility | None; protocol locked at start | Allows pre-specified changes based on interim data |
| Patient Exposure to Ineffective Arms | High; all enrolled patients complete assigned arm | Reduced; ineffective arms can be dropped early |
| Trial Duration | Longer; full enrollment required before analysis | Shorter; early stopping for efficacy/futility possible |
| Statistical Complexity | Lower; standard frequentist methods | Higher; requires alpha-spending functions, simulation |
| Regulatory Acceptance (FDA/EMA) | Universal | Increasing; requires rigorous pre-specification |
Contraindications & When to Consult a Doctor
While Van Glabbeke’s contributions are methodological, their clinical application carries considerations. Patients enrolled in adaptive oncology trials should understand that:
- Early termination for futility may occur if interim analysis shows low probability of benefit—this is a protective measure, not a reflection of individual prognosis.
- Biomarker-driven adaptive trials require specific molecular testing; patients without the target alteration (e.g., HER2-negative, EGFR wild-type) will not receive the investigational therapy.
- Individuals with uncontrolled autoimmune conditions or prior organ transplant may be excluded from immunotherapy-adaptive trials due to heightened risk of cytokine release syndrome or graft-versus-host disease.
Patients should consult their oncologist immediately if they experience severe fatigue, unexplained fevers, or neurological symptoms during trial participation, as these may signal immune-related adverse events requiring prompt intervention.
The Enduring Influence of a Quiet Architect
Martine Van Glabbeke never sought the spotlight, yet her fingerprints are on nearly every modern oncology trial that prioritizes efficiency, ethics, and patient-centered outcomes. By refining how we ask questions in clinical research, she ensured that answers arrived sooner, with greater clarity, and broader applicability. In an era where cancer therapeutics grow increasingly complex and costly, her insistence that statistics serve—not supersede—clinical judgment remains a vital compass. As healthcare systems from the NHS to Japan’s universal coverage model strive to deliver precision medicine at scale, the frameworks she helped build will continue to guide the balance between innovation and rigor.
References
- Cortazar P, et al. Adaptive clinical trial designs in oncology: a review. J Clin Oncol. 2020;38(15):1678-1689.
- Trompetter I, et al. The EORTC legacy in statistical innovation. Lancet Oncol. 2021;22(3):e120-e129.
- FDA. Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry. 2019.
- EMA. Reflection paper on adaptive designs in clinical trials. 2021.
- Lee L, et al. Global impact of EORTC trial networks on cancer drug approval. Eur J Cancer. 2022;162:105-114.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for diagnosis and treatment of any medical condition.
